Telix Pharmaceuticals Limited (TLX)
Automate Your Wheel Strategy on TLX
With Tiblio's Option Bot, you can configure your own wheel strategy including TLX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TLX
- Rev/Share 0.0
- Book/Share 0.0
- PB 0.0
- Debt/Equity 1.0233
- CurrentRatio 2.7759
- ROIC 0.0606
- MktCap 8477664955.18
- FreeCF/Share 0.0
- PFCF 942.2769
- PE 0.0
- Debt/Assets 0.3834
- DivYield 0
- ROE 0.1392
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TLX | Wedbush | -- | Outperform | -- | $22 | June 5, 2025 |
News
Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved a label expansion for Illuccix® (kit for the preparation of gallium Ga-68 gozetotide, for injection) to include patient selection for radioligand therapy (RLT) in the pre-taxane setting.
Read More
Telix Investor Day in New York City on June 11, 2025: Presenting KOLs
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
MELBOURNE, Australia and INDIANAPOLIS, June 03, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) provides further details on the agenda for the Company's Investor Day to be held on Wednesday, June 11, 2025, at The Yale Club in New York City, from 8.30am ET (10.30pm AEST) to 12.00pm ET.
Read More
Shareholders that Lost Money on Telix Pharmaceuticals Limited (TLX) Should Contact Levi & Korsinsky About Securities Fraud Investigation - TLX
Published: May 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX) concerning possible violations of federal securities laws. On April 28, 2025, Telix issued a press release announcing that the FDA issued a Complete Response Letter denying approval of Telix's New Drug Application for TLX101-CDx ("Pixclara").
Read More
ATTENTION Telix Pharmaceuticals Limited Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
Published: May 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX) concerning possible violations of federal securities laws. On April 28, 2025, Telix issued a press release announcing that the FDA issued a Complete Response Letter denying approval of Telix's New Drug Application for TLX101-CDx ("Pixclara").
Read More
TLX STOCK ALERT: Levi & Korsinsky Notifies Telix Pharmaceuticals Limited Investors of an Ongoing Investigation
Published: May 01, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX) concerning possible violations of federal securities laws. On April 28, 2025, Telix issued a press release announcing that the FDA issued a Complete Response Letter denying approval of Telix's New Drug Application for TLX101-CDx ("Pixclara").
Read More
TLX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Telix Pharmaceuticals Limited
Published: April 30, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX) concerning possible violations of federal securities laws. On April 28, 2025, Telix issued a press release announcing that the FDA issued a Complete Response Letter denying approval of Telix's New Drug Application for TLX101-CDx ("Pixclara").
Read More
Levi & Korsinsky Announces an Investigation on Behalf of Telix Pharmaceuticals Limited (TLX) Shareholders Who May Have Been Affected by Fraud
Published: April 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX) concerning possible violations of federal securities laws. On April 28, 2025, Telix issued a press release announcing that the FDA issued a Complete Response Letter denying approval of Telix's New Drug Application for TLX101-CDx ("Pixclara").
Read More
Telix Reports US$186M Q1 Revenue, Up 62% YOY
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Telix Pharmaceuticals reported strong Q1 2025 revenue of $186 million, up 62% year-on-year, driven by Illuccix® sales and RLS Radiopharmacies acquisition.
Read More
All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy
Published: April 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Telix Pharmaceuticals Limited (TLX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Telix Shares May Gain on the Distribution Deal With Cardinal Health
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
TLX rolls out a new e-commerce platform connecting users to top retail pharmacies, aiming to boost savings, improve access, and expand its digital health services.
Read More
About Telix Pharmaceuticals Limited (TLX)
- IPO Date 2024-11-14
- Website https://telixpharma.com
- Industry Biotechnology
- CEO Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, MBA
- Employees None